Criteria for assessing high-priority drug-drug interactions for clinical decision support in electronic health records

BMC Medical Informatics and Decision Making

Volumn 13, Issue 1, 2013, Pages

  Phansalkar, Shobha ^a,b   Desai, Amrita ^a   Choksi, Anish ^e   Yoshida, Eileen ^a   Doole, John ^a   Czochanski, Melissa ^a   Tucker, Alisha D ^a   Middleton, Blackford ^a,b   Bell, Douglas ^c,d   Bates, David W ^a,b  

^a PARTNERS HEALTHCARE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c RAND CORPORATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Alerts; Clinical decision support; Drug drug interaction; Electronic health record; Medication related decision support system

Indexed keywords

DECISION SUPPORT SYSTEM; DRUG INTERACTION; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; HOSPITAL INFORMATION SYSTEM; HUMAN; KNOWLEDGE BASE; REPRODUCIBILITY; REVIEW; STANDARD;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG INTERACTIONS; ELECTRONIC HEALTH RECORDS; HUMANS; KNOWLEDGE BASES; MEDICAL ORDER ENTRY SYSTEMS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 84878818516     PISSN: None     EISSN: 14726947     Source Type: Journal    
DOI: 10.1186/1472-6947-13-65     Document Type: Article

References (41)

1. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. Jha AK, Laguette J, Seger A, Bates DW, J Am Med Inform Assoc 2008 15 5 647 653 10.1197/jamia.M2634 18579834
2. Medication-related clinical decision support in computerized provider order entry systems: a review. Kuperman GJ, Bobb A, Payne TH, Avery AJ, Gandhi TK, Burns G, Classen DC, Bates DW, J Am Med Inform Assoc 2007 14 1 29 40 17068355 (Pubitemid 44909484)
3. Reasons for physician non-adherence to electronic drug alerts. Taylor LK, Tamblyn R, Stud Health Technol Inform 2004 107 Pt 2 1101 1105 15360983
4. Overriding of drug safety alerts in computerized physician order entry. van der Sijs H, Aarts J, Vulto A, Berg M, J Am Med Inform Assoc 2006 13 2 138 147 10.1197/jamia.M1809 16357358 (Pubitemid 43332904)
5. Analysis of overridden alerts in a drug-drug interaction detection system. Mille F, Schwartz C, Brion F, Fontan JE, Bourdon O, Degoulet P, Jaulent MC, Int J Qual Health Care 2008 20 6 400 405 10.1093/intqhc/mzn038 18784269
6. Turning off frequently overridden drug alerts: limited opportunities for doing it safely. van der Sijs H, Aarts J, van Gelder T, Berg M, Vulto A, J Am Med Inform Assoc 2008 15 4 439 448 10.1197/jamia.M2311 18436915 (Pubitemid 351885159)
7. Preventable medication errors: identifying and eliminating serious drug interactions. Peterson JF, Bates DW, J Am Pharm Assoc (Wash) 2001 41 2 159 160
8. Stage 1 Meaningful Use Certification Criteria Standards, [ http://healthit.hhs.gov/media/MU/n508/MU-SCC-CombinedGrid.pdf ]
9. CMS EHR Meaningful Use Overview, [ https://www.cms.gov/ EHRIncentivePrograms/30-Meaningful-Use.asp ]
10. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Wong CM, Ko Y, Chan A, Ann Pharmacother 2008 42 12 1737 1748 10.1345/aph.1L255 19033481
11. Health Information Technology, Initial Set of Standards, Implementation Specifications, and Certifications Criteria for Electronic Health Record Technology Title 45 Code of Federal Regulations, Pt. 170. 2010 ed
12. High-priority drug-drug interactions for use in electronic health records. Phansalkar S, Desai AA, Bell DS, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW, J Am Med Inform Assoc 2012 19 5 735 743 10.1136/amiajnl-2011-000612 22539083
13. ORCA: OpeRational ClassificAtion of drug interactions. Hansten PD, Horn JR, Hazlet TK, J Am Pharm Assoc (Wash) 2001 41 2 161 165
14. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. Malone DC, Abarca J, Hansten PD, Grizzle AJ, Armstrong EP, Van Bergen RC, Duncan-Edgar BS, Solomon SL, Lipton RB, J Am Pharm Assoc (2003) 2004 44 2 142 151 10.1331/154434504773062591
15. Frequency and nature of drug-drug interactions in a Dutch university hospital. Zwart-van Rijkom JE, Uijtendaal EV, ten Berg MJ, van Solinge WW, Egberts AC, Br J Clin Pharmacol 2009 68 2 187 193 10.1111/j.1365-2125.2009. 03443.x 19694737
16. Clinician's assessments of outpatient electronic medical record alert and reminder usability and usefulness requirements. Krall MA, Sittig DF, Proc AMIA Symp 2002 400 404
17. Improving sedative-hypnotic prescribing in older hospitalized patients: provider-perceived benefits and barriers of a computer-based reminder. Agostini JV, Concato J, Inouye SK, J Gen Intern Med 2008 23 Suppl 1 32 36 18095041 (Pubitemid 350295387)
18. Adverse drug events prevention rules: multi-site evaluation of rules from various sources. Chazard E, Ficheur G, Merlin B, Serrot E, Beuscart R, Stud Health Technol Inform 2009 148 102 111 19745240
19. Proposal for a new tool to evaluate drug interaction cases. Horn JR, Hansten PD, Chan LN, Ann Pharmacother 2007 41 4 674 680 10.1345/aph.1H423 17389673 (Pubitemid 46625492)
20. Clinical decision support provided within physician order entry systems: a systematic review of features effective for changing clinician behavior. Kawamoto K, Lobach DF, AMIA Annu Symp Proc 2003 361 365
21. Practitioners' views on computerized drug-drug interaction alerts in the VA system. Ko Y, Abarca J, Malone DC, Dare DC, Geraets D, Houranieh A, Jones WN, Nichol WP, Schepers GP, Wilhardt M, J Am Med Inform Assoc 2007 14 1 56 64 17068346 (Pubitemid 44909483)
22. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Olvey EL, Clauschee S, Malone DC, Clin Pharmacol Ther 2010 87 1 48 51 10.1038/clpt.2009. 198 19890252
23. Drug interaction classification systems. Horn JR, Hansten PD, Pharm Times 2004 8 8148
24. Developing and implementing clinical decision support for use in a computerized prescriber-order-entry system. Chaffee BW, Zimmerman CR, Am J Health Syst Pharm 2010 67 5 391 400 10.2146/ajhp090153 20172991
25. Stopping medications can cause adverse effects. Horn JR, Hansten PD, Pharm Times 2008 1 8364
26. Tiering drug-drug interaction alerts by severity increases compliance rates. Paterno MD, Maviglia SM, Gorman PN, Seger DL, Yoshida E, Seger AC, Bates DW, Gandhi TK, J Am Med Inform Assoc 2009 16 1 40 46 10.1197/jamia.M2808 18952941
27. Reasons provided by prescribers when overriding drug-drug interaction alerts. Grizzle AJ, Mahmood MH, Ko Y, Murphy JE, Armstrong EP, Skrepnek GH, Jones WN, Schepers GP, Nichol WP, Houranieh A, et al. Am J Manag Care 2007 13 10 573 578 17927462
28. Physicians' decisions to override computerized drug alerts in primary care. Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, Phillips RS, Arch Intern Med 2003 163 21 2625 2631 10.1001/archinte.163.21.2625 14638563 (Pubitemid 37464421)
29. Central nervous system excitatory effects of meperidine in cancer patients. Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Rogers AG, Inturrisi CE, Reidenberg MM, Ann Neurol 1983 13 2 180 185 10.1002/ana.410130213 6187275 (Pubitemid 13188214)
30. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Lee LJ, Hafkin B, Lee ID, Hoh J, Dix R, Antimicrob Agents Chemother 1997 41 10 2196 2200 9333047 (Pubitemid 27422212)
31. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Lehto P, Kivisto KT, Antimicrob Agents Chemother 1994 38 2 248 251 10.1128/AAC.38.2.248 8192452 (Pubitemid 24054242)
32. Successful strategy to improve the specificity of electronic statin-drug interaction alerts. Seidling HM, Storch CH, Bertsche T, Senger C, Kaltschmidt J, Walter-Sack I, Haefeli WE, Eur J Clin Pharmacol 2009 65 11 1149 1157 10.1007/s00228-009-0704-x 19641913
33. Hansten PD, Horn JR, Drug Interactions: Analysis and Management Wolters Kluwer Health 2006
34. Drug-drug interaction software quality assurance: Lessons learned. Hines LE, Warholak TL, Saverno KR, Boesen MD, Sisk MA, Malone DC, J Am Pharm Assoc (2003) 2011 51 5 570 572 10.1331/JAPhA.2011.10231
35. General practitioners' perceptions of the pharmaceutical decision-support tools in their prescribing software. Ahearn MD, Kerr SJ, Med J Aust 2003 179 1 34 37 12831382 (Pubitemid 36896191)
36. Data quality in the outpatient setting: impact on clinical decision support systems. Berner ES, Kasiraman RK, Yu F, Ray MN, Houston TK, AMIA Annu Symp Proc 2005 41 45
37. Implementation of rules based computerised bedside prescribing and administration: intervention study. Nightingale PG, Adu D, Richards NT, Peters M, BMJ 2000 320 7237 750 753 10.1136/bmj.320.7237.750 10720357 (Pubitemid 30179422)
38. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM, Blood 2011 118 24 6269 6273 10.1182/blood-2011-08-335612 21911832
39. Overrides of medication alerts in ambulatory care. Isaac T, Weissman JS, Davis RB, Massagli M, Cyrulik A, Sands DZ, Weingart SN, Arch Intern Med 2009 169 3 305 311 10.1001/archinternmed.2008.551 19204222
40. Clinical relevance of drug-drug interactions: a structured assessment procedure. van Roon EN, Flikweert S, le Comte M, Langendijk PN, Kwee-Zuiderwijk WJ, Smits P, Brouwers JR, Drug Saf 2005 28 12 1131 1139 10.2165/00002018- 200528120-00007 16329715 (Pubitemid 41776003)
41. Linking laboratory and pharmacy: opportunities for reducing errors and improving care. Schiff GD, Klass D, Peterson J, Shah G, Bates DW, Arch Intern Med 2003 163 8 893 900 10.1001/archinte.163.8.893 12719197 (Pubitemid 36519735)